|
1
|
Stable isotopes, . http://chemistry.tutorvista.com/inorganic-chemistry/stable-and-unstable-isotopes.htmlApril
16–2017
|
|
2
|
Nuclear Medicine: Medical isotopes:
General concepts. https://www.radiochemistry.org/nuclearmedicine/radioisotopes/01_isotopes.shtml#topApril
16–2017
|
|
3
|
American Nuclear Society: Medical use of
radioisotopes. 2014, http://www.nuclearconnect.org
|
|
4
|
Australian Nuclear Science Technology
Organisation: What are radioisotopes? http://www.ansto.gov.au/NuclearFacts/AboutNuclearScience/RadioisotopesApril
16–2017
|
|
5
|
World Nuclear Association: Radioisotopes
in medicine. http://www.world-nuclear.org/information-library/non-power-nuclear-applications/radioisotopes-research/radioisotopes-in-medicine.aspx(Updated
December 2016). April. 2017
|
|
6
|
Zalutsky MR: Radionuclide therapyHandbook
of Nuclear Chemistry: Radiochemistry and Radiopharmaceutical
Chemistry in Life Sciences. Roesch F: 4. Kluwer Academic;
Dordrecht: pp. 315–348. 2003
|
|
7
|
Harris TJR, Kalen JD and Hall J: Report of
meeting held to discuss existing and future radionuclide
requirements for the national cancer institute. https://www.isotopes.gov/outreach/reports/Radionuclide_Report.pdf
|
|
8
|
Nordberg E, Orlova A, Friedman M,
Tolmachev V, Ståhl S, Nilsson FY, Glimelius B and Carlsson J: In
vivo and in vitro uptake of 111In, delivered
with the affibody molecule (ZEGFR:955)2, in
EGFR expressing tumour cells. Oncol Rep. 19:853–857.
2008.PubMed/NCBI
|
|
9
|
Sabongi JG, Gonçalves MC, Alves CD, Alves
J, Scapulatempo-Neto C and Moriguchi SM: Lutetium 177-DOTA-TATE
therapy for esthesioneuroblastoma: A case report. Exp Ther Med.
12:3078–3082. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bobeica M, Niculae D, Balabanski D,
Filipescu D, Gheorghe I, Ghita DG and Luo W: Radioisotope
production for medical applications at ELI-NP. Rom Rep Phys. 68
Suppl:847–83. 2016.
|
|
11
|
Cutler CS, Chanda N, Shukla R, Sisay N,
Cantorias M, Zambre A, McLaughlin M, Kelsey J, Upenandran A,
Robertson D, et al: Nanoparticles and phage display selected
peptides for imaging and therapy of cancer. In: Theranostics,
Gallium-68 and Other RadionuclidesRecent Results in Cancer
Research. 194. Baum RP and Rosch F: Springer; Heidelberg: pp.
133–147. 2013, View Article : Google Scholar : PubMed/NCBI
|
|
12
|
National Research Council (US) and
Institute of Medicine (US) Committee on State of the Science of
Nuclear Medicine: Advancing nuclear medicine through innovation.
National Academies Press; Washington, DC: 2007
|
|
13
|
Kwekkeboom DJ, Mueller-Brand J, Paganelli
G, Anthony LB, Pauwels S, Kvols LK, O'dorisio TM, Valkema R, Bodei
L, Chinol M, et al: Overview of results of peptide receptor
radionuclide therapy with 3 radiolabeled somatostatin analogs. J
Nucl Med. 46 Suppl 1:62–66. 2005.
|
|
14
|
Emmet L, Willowson K, Violet J, Shin J,
Blanksby A and Lee J: Lutetium177 PSMA radionuclide therapy for men
with prostate cancer: A review of the current literature and
discussion of practical aspects of therapy. J Med Radiat Sci.
64:52–60. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Weill Cornell Medicine: Using radiation,
radioimmunotherapy and radioactive isotopes such as lutetium 177 to
treat prostate cancer. https://weillcornellgucancer.org/2017/01/12/using-radiation-radioimmunotherapy-and-radioactive-isotopes-such-as-lutetium-177-to-treat-prostate-cancerApril
16–2017
|
|
16
|
Ahmadzadehfar H, Rahbar K, Kürpig S,
Bögemann M, Claesener M, Eppard E, Gärtner F, Rogenhofer S,
Schäfers M and Essler M: Early side effects and first results of
radioligand therapy with (177)Lu-DKFZ-617 PSMA of
castrate-resistant metastatic prostate cancer: a two-centre study.
EJNMMI Res. 5:1142015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rahbar K, Ahmadzadehfar H, Kratochwil C,
Haberkorn U, Schäfers M, Essler M, Baum RP, Kulkarni HR, Schmidt M,
Drzezga A, et al: German multicenter study investigating
177Lu-PSMA-617 radioligand therapy in advanced prostate
cancer patients. J Nucl Med. 58:85–90. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rahbar K, Schmidt M, Heinzel A, Eppard E,
Bode A, Yordanova A, Claesener M and Ahmadzadehfar H: Response and
tolerability of a single dose of 177Lu-PSMA-617 in
patients with metastatic castration-resistant prostate cancer: A
multicenter retrospective analysis. J Nucl Med. 57:1334–1338. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Strosberg J, El-Haddad G, Wolin E,
Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H,
et al: NETTER-1 Trial Investigators: Phase 3 trial of
177Lu-Dotatate for midgut neuroendocrine tumors. N Engl
J Med. 376:125–135. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
van Hazel GA, Heinemann V, Sharma NK,
Findlay MP, Ricke J, Peeters M, Perez D, Robinson BA, Strickland
AH, Ferguson T, et al: SIRFLOX: Randomized phase III trial
comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus
mFOLFOX6 (plus or minus bevacizumab) plus selective internal
radiation therapy in patients with metastatic colorectal cancer. J
Clin Oncol. 34:1723–1731. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Weigert O, Illidge T, Hiddemann W and
Dreyling M: Recommendations for the use of yttrium-90 ibritumomab
tiuxetan in malignant lymphoma. Cancer. 107:686–695. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kaminski MS, Tuck M, Estes J, Kolstad A,
Ross CW, Zasadny K, Regan D, Kison P, Fisher S, Kroll S and Wahl
RL: 131I-tositumomab therapy as initial treatment for
follicular lymphoma. N Engl J Med. 352:441–449. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ocean AJ, Pennington KL, Guarino MJ,
Sheikh A, Bekaii-Saab T, Serafini AN, Lee D, Sung MW, Gulec SA,
Goldsmith SJ, et al: Fractionated radioimmunotherapy with (90)
Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in
advanced pancreatic cancer: A phase 1 trial. Cancer. 118:5497–5506.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tuttle RM: Differentiated thyroid cancer:
Radioiodine treatment. Ross DS and Mulder JE: https://www.uptodate.com/contents/differentiated-thyroid-cancer-radioiodine-treatment?source=see_linkApril
18–2017 View Article : Google Scholar
|
|
25
|
Nixon IJ, Ganly I, Patel SG, Palmer FL, Di
Lorenzo MM, Grewal RK, Larson SM, Tuttle RM, Shaha A and Shah JP:
The results of selective use of radioactive iodine on survival and
on recurrence in the management of papillary thyroid cancer, based
on Memorial Sloan-Kettering Cancer Center risk group
stratification. Thyroid. 23:683–694. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
American Thyroid Association (ATA)
Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid
Cancer, . Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL,
Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, et
al: Revised American Thyroid Association management guidelines for
patients with thyroid nodules and differentiated thyroid cancer.
Thyroid. 19:1167–1214. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Barbolosi D, Summer I, Meille C, Serre R,
Kelly A, Zerdoud S, Bournaud C, Schvartz C, Toubeau M, Toubert ME,
et al: Modeling therapeutic response to radioiodine in metastatic
thyroid cancer: A proof-of-concept study for individualized
medicine. Oncotarget. 8:39167–39176. 2017.PubMed/NCBI
|
|
28
|
Harrington KJ, Mohammadtaghi S, Uster PS,
Glass D, Peters AM, Vile RG and Stewart JS: Effective targeting of
solid tumors in patients with locally advanced cancers by
radiolabeled pegylated liposomes. Clin Cancer Res. 7:243–254.
2001.PubMed/NCBI
|
|
29
|
Stefanescu DC, Ceachir O, Zainea V,
Hainarosie M, Pietrosanu C, Ionita IG and Hainarosie R: Methilene
blue video contact endoscopy enhancing methods. Rev Chim.
67:1558–1559. 2016.
|
|
30
|
Hainarosie R, Ceachir O, Zainea V,
Hainarosie M, Pietrosanu C, Zamfir C and Stefanescu DC: The test of
lugol iodine solution associated with NBI examination in early
diagnostic of tongue carcinoma. Rev Chim. 68:226–227. 2017.
|
|
31
|
Stefanescu DC, Ceachir O, Zainea V,
Hainarosie M, Pietrosanu C, Ionita IG and Hainarosie R: The use
ofmethylene blue in assessing disease free margins during
CO2 LASER assisted direct laryngoscopy for glottis
cancer. Rev Chim. 67:1327–1328. 2016.
|
|
32
|
Hainarosie R, Zainea V, Ceachir O,
Hainarosie M, Pietrosanu C and Stefanescu DC: The use of methylene
blue in early detection of the vocal fold cancer. Rev Chim.
68:16–17. 2017.
|
|
33
|
Stefanescu DC, Ceachir O, Zainea V,
Hainarosie M, Pietrosanu C, Ionita IG and Hainarosie R: The value
of toluidine blue staining test in assessing disease free margins
of oral cavity carcinomas. Rev Chim. 67:1255–1256. 2016.
|
|
34
|
Petrică-Matei GG, Iordache F, Hainăroşie R
and Bostan M: Characterization of the tumor cells from human head
and neck cancer. Rom J Morphol Embryol. 57 Suppl:791–799.
2016.PubMed/NCBI
|
|
35
|
Lam MG, de Klerk JM and van Rijk PP:
186Re-HEDP for metastatic bone pain in breast cancer
patients. Eur J Nucl Med Mol Imaging. 31 Suppl 1:162–170. 2004.
View Article : Google Scholar : PubMed/NCBI
|
